Disparities in real-world treatment patterns of hypomethylating agents among patients with MDS in the United States. [PDF]
Mukherjee S +13 more
europepmc +1 more source
Albumin does not induce IL-6 release and toll-like receptor activation in vitro: Role of endotoxin contamination and biochemical modifications. [PDF]
Paar M +8 more
europepmc +1 more source
Physical Layer Security Enhancement in IRS-Assisted Interweave CIoV Networks: A Heterogeneous Multi-Agent Mamba RainbowDQN Method. [PDF]
Lin R, Xie S, Chen W, Xu T.
europepmc +1 more source
Comparative efficacy of venetoclax and hypomethylating agents in acute myeloid leukemia treatment: a meta-analysis of clinical trials and Real-World outcomes. [PDF]
Sanz-Solas A +6 more
europepmc +1 more source
Unmet needs in patients with acute myeloid leukemia ineligible for intensive approaches: perspectives from a European expert panel. [PDF]
Ferrara F +4 more
europepmc +1 more source
Novel approaches to the use of hypomethylating agents in myeloid malignancies. [PDF]
Cheng J, O'Connell C, O'Connell C.
europepmc +1 more source
Reply to: Late Nonrelapse Mortality: A Hidden Risk in Triplet Therapy for <i>IDH</i>-Mutated AML? [PDF]
Marvin-Peek J, DiNardo CD.
europepmc +1 more source
A Phase 2 study of CPX-351 in combination with venetoclax in patients with newly diagnosed high-risk acute myeloid leukemia. [PDF]
Jen WY +18 more
europepmc +1 more source

